Drug intelligence / Profile preview

antofloxacin

Development stage: Unknown
Lead developer: Shanghai Institute of Materia Medica
Modality: Small Molecules
Administration: Oral

Overview

Antofloxacin is a synthetic broad-spectrum antibacterial agent of the fluoroquinolone class. It acts primarily by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription. Developed as a new molecular entity in China, it is used to treat infections such as acute exacerbation of chronic bronchitis and acute pyelonephritis[2][3][5][7]. Its mechanism of action is similar to other fluoroquinolones but with distinct pharmacokinetic properties.

Brand names: none found
Other names: antofloxacin hydrochloride(S)-antofloxacin hydrochloride119354-43-7UNII-56A192VX1QUNII56A192VX1QUNII 56A192VX1Q

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on antofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on antofloxacin.

Explore the full profile